Yarrow Bioscience
YARW
41 hedge funds and large institutions have $9.44M invested in Yarrow Bioscience in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
17% more capital inflows, than outflows
Capital inflows: $1.41M | Capital outflows: $1.2M
0.88% more ownership
Funds ownership: 42.64% → 43.52% (+0.88%)
5% less funds holding
Funds holding: 43 → 41 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ADAR1 Capital Management
Austin,
Texas
|
+$1.22M |
| 2 |
GSA Capital Partners
London,
United Kingdom
|
+$46.4K |
| 3 |
Superstring Capital Management
New York
|
+$39.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.7K |
| 5 |
Two Sigma Securities
New York
|
+$26.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Anson Funds Management
Dallas,
Texas
|
-$797K |
| 2 |
Shay Capital
New York
|
-$100K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$78.6K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
-$51.7K |
| 5 |
Boothbay Fund Management
New York
|
-$48.6K |
YARW Hedge Fund Activity: Q2 2026 in Review
41 of the 8,370 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q2 2026, worth a combined $9.44M — up 11% from $8.49M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of YARW and 4 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 6 added.
The largest buyer was ADAR1 Capital Management, adding an estimated $1.22M. The largest seller was Anson Funds Management, cutting an estimated $797K.
- 41 institutional investors held Yarrow Bioscience (YARW) as of Q2 2026, down from 43 in Q1 2026.
- Funds reported $9.44M of Yarrow Bioscience stock for Q2 2026, up 11% quarter-over-quarter.
- 4 funds opened new Yarrow Bioscience positions in Q2 2026 and 5 closed out, a net change of -1 holder.
- The largest Yarrow Bioscience buyer in Q2 2026 was ADAR1 Capital Management, an estimated $1.22M added.
- The largest Yarrow Bioscience seller in Q2 2026 was Anson Funds Management, an estimated $797K sold.
Based on aggregated 13F filings for Q2 2026.